HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis.

AbstractBACKGROUND:
The platelet activating factor (PAF) antagonist, Lexipafant, has been used in experimental models and clinical trials to treat severe acute pancreatitis (AP). The purpose of this study was to determine whether Lexipafant reduces the local and systemic components of AP in a murine model of mild, edematous AP.
MATERIALS AND METHODS:
Forty-eight female Swiss-Webster mice were divided into four groups. Group 1 received 50 microl of saline ip every hour for 6 h (sham). Group 2 received saline treatment, plus Lexipafant (25 mg/kg dose ip, every 3 h starting 1 h after the first saline injection) (sham/Lex). Group 3 received cerulein (50 microg/kg dose ip, every hour for 6 h) (AP). Group 4 received AP, plus therapeutic treatment with Lexipafant (AP/Lex). Animals were sacrificed 3 h after the last injection. Serum cytokine levels were determined by ELISA. Standard assays were performed for serum amylase activity and lung myeloperoxidase activity (MPO). Histology was scored by two blinded investigators.
RESULTS:
Serum cytokines (TNFalpha, IL-1beta), lung MPO, and serum amylase activity were reduced by PAF antagonism. Histology showed a trend toward improvement with Lexipafant, but did not reach statistical significance.
CONCLUSION:
The PAF antagonism reduces the severity of systemic inflammation when given after the induction of mild AP in mice. These results suggest that Lexipafant may be useful in the treatment of mild pancreatitis after its clinical onset.
AuthorsJ S Lane, K E Todd, B Gloor, C F Chandler, A W Kau, S W Ashley, H A Reber, D W McFadden
JournalThe Journal of surgical research (J Surg Res) Vol. 99 Issue 2 Pg. 365-70 (Aug 2001) ISSN: 0022-4804 [Print] United States
PMID11469912 (Publication Type: Journal Article)
CopyrightCopyright 2001 Academic Press.
Chemical References
  • Imidazoles
  • Interleukin-1
  • Platelet Activating Factor
  • Tumor Necrosis Factor-alpha
  • Peroxidase
  • Amylases
  • Leucine
  • lexipafant
Topics
  • Acute Disease
  • Amylases (blood)
  • Animals
  • Disease Models, Animal
  • Female
  • Imidazoles (pharmacology)
  • Interleukin-1 (blood)
  • Leucine (analogs & derivatives, pharmacology)
  • Lung (immunology, metabolism)
  • Mice
  • Pancreatitis (drug therapy, immunology, pathology)
  • Peroxidase (analysis)
  • Platelet Activating Factor (antagonists & inhibitors, immunology)
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: